Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of ASKA Pharmaceutical Holdings Co., Ltd.. A complete text table follows the diagram.
Pharmaceuticals supply 83% of revenue, with women’s health and internal-medicine products growing as R&D and Vietnam expansion weigh on profit.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Pharmaceutical business | 1 | 29.3B | 83.0% of reported total |
| Animal health business | 1 | 3.8B | 10.7% of reported total |
| Oversea business | 1 | 2.1B | 6.1% of reported total |
| Other operating segments | 1 | 99M | 0.3% of reported total |
| Other & rounding | 1 | 1M | 0.0% of reported total |
| Revenues From External Customers | 2 | 35.3B | Reported six-month total · ¥35.3B |
| Operating profit | 3 | 2.6B | 7.5% operating margin |
| Operating costs & expenses | 3 | 32.6B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 2.8B | Reported pretax result |
| R&D and overseas expansion | 3 | 107M | Revenue rose to JPY35.253B, but JPY3.703B of research spending and the integration of Vietnam's Ha Tay Pharmaceutical reduced operating profit to JPY2.649B. |
| Net profit attributable to owners | 5 | 2.2B | Reported parent-company result |
| Tax, attribution & other | 5 | 530M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Pharmaceutical business | Revenues From External Customers | 29.3B |
| Animal health business | Revenues From External Customers | 3.8B |
| Oversea business | Revenues From External Customers | 2.1B |
| Other operating segments | Revenues From External Customers | 99M |
| Other & rounding | Revenues From External Customers | 1M |
| Revenues From External Customers | Operating profit | 2.6B |
| Revenues From External Customers | Operating costs & expenses | 32.6B |
| Operating profit | Profit before tax | 2.6B |
| R&D and overseas expansion | Profit before tax | 107M |
| Profit before tax | Net profit attributable to owners | 2.2B |
| Profit before tax | Tax, attribution & other | 530M |